Understand the source comparison
Peptides for Joint Health: Research vs Clinical Comparison
BPC-157 VEGF upregulation, angiogenesis, fibroblast recruitment 250–500 mcg/day Subcutaneous or IM near injury site Preclinical animal studies; no Phase 3 human trials Most robust preclinical data for acute soft tissue injury; lacks FDA approval for human use
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis, fibroblast recruitment
- 250–500 mcg/day
- Subcutaneous or IM near injury site
- Preclinical animal studies; no Phase 3 human trials
- Most robust preclinical data for acute soft tissue injury; lacks FDA approval for human use
- TB-500
- Actin binding, cytokine modulation, reduced fibrosis
- 2–2.5mg twice weekly (loading), 2mg weekly (maintenance)
- Subcutaneous (systemic)
- Preclinical data; limited human case reports
- Effective for chronic inflammation; longer protocol required; systemic effects
- Collagen Peptides
- Amino acid substrates for cartilage matrix synthesis
- 10–15g/day
- Oral
- Multiple RCTs in humans; FDA GRAS status
- Best evidence for systemic cartilage support; requires 8–12 weeks minimum; safe for long-term use
- Glucosamine/Chondroitin
- Proposed GAG synthesis support
- 1500mg/1200mg daily
- Mixed evidence; Cochrane review shows modest benefit
- Inconsistent clinical outcomes; slower onset than peptides; often combined with collagen